268 related articles for article (PubMed ID: 18403491)
1. Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors.
Sampson JH; Akabani G; Archer GE; Berger MS; Coleman RE; Friedman AH; Friedman HS; Greer K; Herndon JE; Kunwar S; McLendon RE; Paolino A; Petry NA; Provenzale JM; Reardon DA; Wong TZ; Zalutsky MR; Pastan I; Bigner DD
Neuro Oncol; 2008 Jun; 10(3):320-9. PubMed ID: 18403491
[TBL] [Abstract][Full Text] [Related]
2. Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning.
Sampson JH; Brady ML; Petry NA; Croteau D; Friedman AH; Friedman HS; Wong T; Bigner DD; Pastan I; Puri RK; Pedain C
Neurosurgery; 2007 Feb; 60(2 Suppl 1):ONS89-98; discussion ONS98-9. PubMed ID: 17297371
[TBL] [Abstract][Full Text] [Related]
3. Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors.
Sampson JH; Akabani G; Archer GE; Bigner DD; Berger MS; Friedman AH; Friedman HS; Herndon JE; Kunwar S; Marcus S; McLendon RE; Paolino A; Penne K; Provenzale J; Quinn J; Reardon DA; Rich J; Stenzel T; Tourt-Uhlig S; Wikstrand C; Wong T; Williams R; Yuan F; Zalutsky MR; Pastan I
J Neurooncol; 2003 Oct; 65(1):27-35. PubMed ID: 14649883
[TBL] [Abstract][Full Text] [Related]
4. Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies.
Kunwar S; Chang SM; Prados MD; Berger MS; Sampson JH; Croteau D; Sherman JW; Grahn AY; Shu VS; Dul JL; Husain SR; Joshi BH; Pedain C; Puri RK
Neurosurg Focus; 2006 Apr; 20(4):E15. PubMed ID: 16709020
[TBL] [Abstract][Full Text] [Related]
5. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group.
Kunwar S; Prados MD; Chang SM; Berger MS; Lang FF; Piepmeier JM; Sampson JH; Ram Z; Gutin PH; Gibbons RD; Aldape KD; Croteau DJ; Sherman JW; Puri RK;
J Clin Oncol; 2007 Mar; 25(7):837-44. PubMed ID: 17327604
[TBL] [Abstract][Full Text] [Related]
6. Induction of hyperintense signal on T2-weighted MR images correlates with infusion distribution from intracerebral convection-enhanced delivery of a tumor-targeted cytotoxin.
Sampson JH; Raghavan R; Provenzale JM; Croteau D; Reardon DA; Coleman RE; Rodríguez Ponce I; Pastan I; Puri RK; Pedain C
AJR Am J Roentgenol; 2007 Mar; 188(3):703-9. PubMed ID: 17312057
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions.
Sampson JH; Raghavan R; Brady ML; Provenzale JM; Herndon JE; Croteau D; Friedman AH; Reardon DA; Coleman RE; Wong T; Bigner DD; Pastan I; Rodríguez-Ponce MI; Tanner P; Puri R; Pedain C
Neuro Oncol; 2007 Jul; 9(3):343-53. PubMed ID: 17435179
[TBL] [Abstract][Full Text] [Related]
8. Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study.
Sampson JH; Reardon DA; Friedman AH; Friedman HS; Coleman RE; McLendon RE; Pastan I; Bigner DD
Neuro Oncol; 2005 Jan; 7(1):90-6. PubMed ID: 15701286
[TBL] [Abstract][Full Text] [Related]
9. Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma.
Parney IF; Kunwar S; McDermott M; Berger M; Prados M; Cha S; Croteau D; Puri RK; Chang SM
J Neurosurg; 2005 Feb; 102(2):267-75. PubMed ID: 15739554
[TBL] [Abstract][Full Text] [Related]
10. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma.
Kunwar S; Chang S; Westphal M; Vogelbaum M; Sampson J; Barnett G; Shaffrey M; Ram Z; Piepmeier J; Prados M; Croteau D; Pedain C; Leland P; Husain SR; Joshi BH; Puri RK;
Neuro Oncol; 2010 Aug; 12(8):871-81. PubMed ID: 20511192
[TBL] [Abstract][Full Text] [Related]
11. Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma.
Weber FW; Floeth F; Asher A; Bucholz R; Berger M; Prados M; Chang S; Bruce J; Hall W; Rainov NG; Westphal M; Warnick RE; Rand RW; Rommell F; Pan H; Hingorani VN; Puri RK
Acta Neurochir Suppl; 2003; 88():93-103. PubMed ID: 14531567
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of convection-enhanced delivery of IL13-Pseudomonas toxin in children with diffuse intrinsic pontine glioma.
Heiss JD; Jamshidi A; Shah S; Martin S; Wolters PL; Argersinger DP; Warren KE; Lonser RR
J Neurosurg Pediatr; 2018 Dec; 23(3):333-342. PubMed ID: 30544335
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of intracerebral convection-enhanced delivery of carboplatin for treatment of recurrent high-grade gliomas.
Wang JL; Barth RF; Cavaliere R; Puduvalli VK; Giglio P; Lonser RR; Elder JB
PLoS One; 2020; 15(12):e0244383. PubMed ID: 33373402
[TBL] [Abstract][Full Text] [Related]
14. Imaging of convection enhanced delivery of toxins in humans.
Mehta AI; Choi BD; Raghavan R; Brady M; Friedman AH; Bigner DD; Pastan I; Sampson JH
Toxins (Basel); 2011 Mar; 3(3):201-6. PubMed ID: 22069706
[TBL] [Abstract][Full Text] [Related]
15. Local delivery of hrBMP4 as an anticancer therapy in patients with recurrent glioblastoma: a first-in-human phase 1 dose escalation trial.
Bos EM; Binda E; Verploegh ISC; Wembacher E; Hoefnagel D; Balvers RK; Korporaal AL; Conidi A; Warnert EAH; Trivieri N; Visioli A; Zaccarini P; Caiola L; van Wijck R; van der Spek P; Huylebroeck D; Leenstra S; Lamfers MLM; Ram Z; Westphal M; Noske D; Legnani F; DiMeco F; Vescovi AL; Dirven CMF
Mol Cancer; 2023 Aug; 22(1):129. PubMed ID: 37563568
[TBL] [Abstract][Full Text] [Related]
16. The IL-4 and IL-13 pseudomonas exotoxins: new hope for brain tumor therapy.
Shimamura T; Husain SR; Puri RK
Neurosurg Focus; 2006 Apr; 20(4):E11. PubMed ID: 16709016
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
Reardon DA; Quinn JA; Rich JN; Desjardins A; Vredenburgh J; Gururangan S; Sathornsumetee S; Badruddoja M; McLendon R; Provenzale J; Herndon JE; Dowell JM; Burkart JL; Newton HB; Friedman AH; Friedman HS
Cancer; 2005 Oct; 104(7):1478-86. PubMed ID: 16088964
[TBL] [Abstract][Full Text] [Related]
18. Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results.
Vogelbaum MA; Sampson JH; Kunwar S; Chang SM; Shaffrey M; Asher AL; Lang FF; Croteau D; Parker K; Grahn AY; Sherman JW; Husain SR; Puri RK
Neurosurgery; 2007 Nov; 61(5):1031-7; discussion 1037-8. PubMed ID: 18091279
[TBL] [Abstract][Full Text] [Related]
19. Clinical studies with targeted toxins in malignant glioma.
Rainov NG; Söling A
Rev Recent Clin Trials; 2006 May; 1(2):119-31. PubMed ID: 18473963
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma.
Rand RW; Kreitman RJ; Patronas N; Varricchio F; Pastan I; Puri RK
Clin Cancer Res; 2000 Jun; 6(6):2157-65. PubMed ID: 10873064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
